---
title: "VK2735 in Chronic weight management: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on VK2735 in Chronic weight management: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 15 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### Approved prescribing information, boxed warnings, contraindications, and REMS

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

#### Subcutaneous formulation: adverse event profile in the phase 2 trial

> “The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use.”
> “The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-3"></a>

#### Subcutaneous formulation: discontinuation and serious adverse events in the phase 2 trial

> “In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug. The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).”
> “A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.”
> “One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-4"></a>

#### Subcutaneous formulation: adverse events of special interest and treatment discontinuation by dose in the phase 2 trial

| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| TEAE leading to treatment discontinuation | “0” | “1 (3)” | “4 (11)” | “4 (11)” | “7 (20)” |
| Treatment-emergent serious adverse events | “1 (3)” | “2 (6)” | “2 (6)” | “2 (6)” | “1 (3)” |
| Pancreatitis | “0” | “0” | “0” | “0” | “0” |
| Gallbladder associated events | “0” | “1 (3)” | “0” | “0” | “1 (3)” |
| Injection site reactions | “3 (9)” | “2 (6)” | “5 (14)” | “5 (14)” | “4 (11)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-5"></a>

#### Subcutaneous formulation: gastrointestinal adverse events with a 5.0 mg starting dose

> “Nausea was highest in the first week in the 15 mg dose group; this group had a 5.0 mg starting dose, rather than the 2.5 mg starting dose in all other treatment groups”
> “GI AEs were generally observed early in the study and subsided over time”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-6"></a>

#### Subcutaneous formulation: heart rate change at week 13 in the phase 2 trial

| Heart rate, bpm | Placebo | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- | --- |
| Baseline, mean (SD) | “74.2 (11.01)” | “69.9 (10.46)” | “70.2 (10.45)” | “71.7 (8.53)” | “69.3 (9.94)” |
| Change from baseline, mean (SD) | “1.4 (12.15)” | “3.3 (11.94)” | “6.1 (9.33)” | “9.3 (8.51)” | “6.9 (8.43)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-7"></a>

#### Subcutaneous formulation: anti-drug antibodies in the phase 2 trial

> “At Week 13, anti‐drug antibodies were detected in between 9% (2.5 mg group) and 23% (10 mg group) of participants in any treatment group”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-8"></a>

#### Subcutaneous formulation: gallstone obstruction and hypoglycemia in the phase 1 multiple ascending dose study

> “One serious adverse event (SAE) was reported in a subject receiving VK2735. A subject with a history of cholelithiasis (gallstones) experienced an SAE of acute choledocholithiasis (gallstone obstruction).”
> “No subjects were discontinued for nausea, vomiting, or GI adverse events. Despite robust activation of the incretin receptor pathways, no hypoglycemia was reported.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.7.1-9"></a>

#### Subcutaneous formulation: tolerability with two-week titration steps and with every-other-week or monthly maintenance

> “One subject (1%) in the induction period discontinued VK2735 treatment due to an adverse event.”
> “Despite the accelerated 2-week titration schedule utilized in this study, rates of common GI adverse events such as nausea, vomiting, constipation, and diarrhea were similar to those reported in the prior Phase 2 study, which utilized 3-week titration steps.”
> “Rates of GI-related adverse events such as vomiting, nausea, diarrhea, and constipation were not meaningfully different from placebo over the 12-week maintenance window.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-2.1.2.7.1-10"></a>

#### Oral formulation: discontinuation and gastrointestinal adverse events in the phase 2 trial

> “During the study 13% of participants receiving placebo discontinued treatment due to an adverse event, compared with 20% of participants receiving VK2735 treatment. The most common reasons for treatment discontinuation were gastrointestinal (GI)-related adverse events. Overall treatment discontinuation rates were 18% among placebo subjects compared with 28% among VK2735 subjects.”
> “Nausea was reported among 58% of participants receiving VK2735 compared with 48% for placebo.”
> “Vomiting was reported in 26% of VK2735-treated subjects compared with 10% among subjects receiving placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-2.1.2.7.1-11"></a>

#### Oral formulation: treatment discontinuation by dose in the phase 2 trial

> “Treatment discontinuations generally dose-dependent; may be related to titration rate”
> “Most common TEAEs leading to discontinuation of drug: nausea, vomiting, constipation”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.7.1-12"></a>

#### Oral formulation: serious and drug-related adverse events by cohort in the phase 1 multiple ascending dose study

| Event, number of subjects (%) | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Drug related TEAEs | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.7.1-13"></a>

#### Oral formulation: company statement on serious adverse events in the phase 1 multiple ascending dose study

> “In addition, oral VK2735 demonstrated encouraging safety and tolerability following 28 days of once-daily dosing, and no serious adverse events (SAEs) have been reported to date.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.7.1-14"></a>

#### Subcutaneous formulation: thyroid, pancreatitis, and calcitonin exclusion criteria in the phase 2 and phase 3 trials

> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-2.1.2.7.1-15"></a>

#### Oral formulation: thyroid, pancreatitis, and calcitonin exclusion criteria in the phase 2 and phase 3 trials

> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-2.1.2.7.1-16"></a>

#### Class context: boxed warning for thyroid C-cell tumors in the tirzepatide (Zepbound) prescribing information

> “In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined”
> “ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
